Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Focus on non-metastatic castration resistant prostate cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 10.02.18
Views: 3203

Professor Noel Clarke and Dr Eric Small

Professor Noel Clarke and Dr Eric Small discuss the latest clinical data presented at the 2018 ASCO Genitourinary Cancers Symposium on the treatment of patients with non-metastatic castration resistant prostate cancer (nmCRPC) with a focus on the PROSPER and SPARTAN trials.

They discuss the rationale for treating patients on the basis of rising PSA and consider the data presented from both studies that addresses whether a rapid PSADT effects final outcomes of treatment.

Professor Clarke and Dr Small address the questions of early vs late treatment for M0 patients and what factors drive the decision to treat.

The conversation also focuses on quality of life data and the importance of monitoring PSA levels in patients with nmCRPC.

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).

Related videos

follow us

Donate to ecancer

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation